Home > Insider Trading > Filing (0001062993-21-001012)

Filing Details

Accession Number:: 0001062993-21-001012
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-02-08 18:37:38
Reporting Period:: 2021-02-08

Accepted Time:: 2021-02-08 18:37:38
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1785345	Landos Biopharma Inc.	LABP	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1164426	Joseph Edelman	51 Astor Place, 10Th Floor New York NY 10003	Yes	No	Yes	No
1224962	Perceptive Advisors Llc	51 Astor Place, 10Th Floor New York NY 10003	Yes	No	Yes	No
1249675	Ltd Fund Master Sciences Life Perceptive	51 Astor Place, 10Th Floor New York NY 10003	Yes	No	Yes	No
1757940	Perceptive Xontogeny Venture Fund, Lp	51 Astor Place, 10Th Floor New York NY 10003	Yes	No	Yes	No
1844296	Xontogeny, Llc	51 Astor Place, 10Th Floor New York NY 10003	Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-02-08	2,941,769	$0.00	2,941,769	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-02-08	2,941,769	$0.00	2,941,769	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-02-08	2,857,795	$0.00	5,799,564	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-02-08	2,857,795	$0.00	5,799,564	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-02-08	1,770,600	$0.00	1,770,600	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-02-08	1,250,000	$16.00	7,049,564	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2021-02-08	2,941,769	$0.00	2,941,769	$0.00
Common Stock	Series A Preferred Stock	Disposition	2021-02-08	2,941,769	$0.00	2,941,769	$0.00
Common Stock	Series B Preferred Stock	Disposition	2021-02-08	2,857,795	$0.00	2,857,795	$0.00
Common Stock	Series B Preferred Stock	Disposition	2021-02-08	2,857,795	$0.00	2,857,795	$0.00
Common Stock	Series B Preferred Stock	Disposition	2021-02-08	1,770,600	$0.00	1,770,600	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	3,090,924	Indirect	See footnote

Footnotes

Each share of the Issuer's Series A preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date.
Each share of the Issuer's Series B preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date.
The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
The securities are directly held by Perceptive Xontogeny Ventures, L.P. ("PXV"). The Advisor serves as the investment manager of PXV, and Perceptive Xontogeny Ventures GP, LLC ("PXV GP") is the general partner of PXV. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
The securities are directly held by PX Venture (A), LLC. The Advisor serves as the investment manager of PXV, and Perceptive Xontogeny Ventures GP, LLC ("PXV GP") is the general partner of PXV. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
The securities are directly held by Xontogeny, LLC ("Xontogeny"). C2 Ventures, LLC ("C2") is the manager of Perceptive XV Holdings, LLC ("Holdings"), the manager of Xontogeny. Joseph Edelman is the managing member of C2. Holdings, C2, and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.